Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

Author： Delpech Y.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.135, Iss.2, 2012-09, pp. : 619-627

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Onapristone, a Progesterone Receptor Antagonist, as First-line Therapy in Primary Breast Cancer

By Robertson J.F.R.   Willsher P.C.   Winterbottom L.   Blamey R.W.   Thorpe S.  

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 214-218

Elsevier

Access to resources Recommend Favorite

Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

By Haarstad Helge   Lønning Per E.   Gundersen Stein   Wist Erik   Raabe Nils   Kvinnsland Stener  

Acta Oncologica, Vol. 37, Iss. 4, 1998-10 ,pp. : 365-368

Informa Healthcare

Access to resources Recommend Favorite

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

By Bjerre Christina  

Acta Oncologica, Vol. 52, Iss. 1, 2013-01 ,pp. : 82-90

Informa Healthcare

Access to resources Recommend Favorite

Vinorelbine, Epirubicin and Fluorouracil as First-Line Therapy in Metastatic Breast Cancer

By Elomaa Inkeri   Joensuu Heikki   Blomqvist Carl  

Acta Oncologica, Vol. 42, Iss. 4, 2003-01 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite